Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | GMNN | O75496 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | BLM | P54132 | 3/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcarnitine SCHEMBL7079427 | 1.00 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL3259109 | 1.00 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL2639482 | 0.98 | LMNA (1.00) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL28744378 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL4749513 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL3004012 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL2515409 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL29376874 | 0.98 | LMNA (1.00) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL20721036 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL27571008 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1791615-A | A process for the preparation of hydroxy polymer esters and their use | CIBA SC HOLDING AG (CH) | 2006-06-21 | — | — | CN | claimed |
| CN-103221038-B | The protective coating of acidic active component | 巴斯夫欧洲公司 | 2019-05-07 | — | — | CN | disclosed |
| US-20170158612-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | THERMOLIFE INTERNATIONAL, LLC | 2017-06-08 | — | — | US | disclosed |
| US-9573883-B2 | Salts of carnitine derivatives and methods of production | THERMOLIFE INTERNATIONAL, LLC (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150166466-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | THERMOLIFE INTERNATIONAL, LLC | 2015-06-18 | — | — | US | disclosed |
| US-20100120917-A1 | BUTYLAMMONIUM MODULATORS OF FATTY ACID TRANSPORT | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120917-A1 | BUTYLAMMONIUM MODULATORS OF FATTY ACID TRANSPORT | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| CN-1791615-A | A process for the preparation of hydroxy polymer esters and their use | CIBA SC HOLDING AG (CH) | 2006-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158612-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | CRAT, SLC25A20, CPT1A | LMNA 943/4885SMN1; SMN2 1516/4885CYP1A2 1530/4885 |
| US-20100120917-A1 | BUTYLAMMONIUM MODULATORS OF FATTY ACID TRANSPORT | SLC27A1, SLC27A2, SLC10A1 | LMNA 1839/4885SMN1; SMN2 3305/4885CYP1A2 829/4885 |
| US-20150166466-A1 | SALTS OF CARNITINE DERIVATIVES AND METHODS OF PRODUCTION | CRAT, SLC25A20, CPT1A | LMNA 943/4885SMN1; SMN2 1516/4885CYP1A2 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.